Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use RIVAROXABAN FOR ORAL SUSPENSION safely and effectively. See full prescribing information for RIVAROXABAN FOR ORAL SUSPENSION. RIVAROXABAN for oral suspension Initial U.S. Approval: 2011
Medication labelWhy this: Advisory · dailymed-prescription
Rivaroxaban for oral suspension is indicated for the treatment of venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment. Rivaroxaban for oral suspension is indicated for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure.
- generic_name
- rivaroxaban
- product_names
- Rivaroxaban
- ndc
- 67877-882, 67877-882-71
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en